Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma

Summary

Phase II trial to study the effectiveness of combining interleukin-12 and interferon alfa in treating patients who have metastatic malignant melanoma. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Interferon alfa may interfere with the growth of the cancer cells. Combining interleukin-12 and interferon alfa may kill more tumor cells.

Timeline

Start

2001-10

Primary completion

2004-07

Completion

—

Drugs

Indications